Online inquiry

IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11351MR)

This product GTTS-WQ11351MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11351MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2278MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ2045MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ10279MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LFG 316
GTTS-WQ4746MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BPS-804
GTTS-WQ10129MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ5820MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ1410MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ8012MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GZ-402668
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW